|
Azacitidine (AZA) Clinical Trials
11 actively recruiting trials across 5 locations
No change since June 2026
Also known as: Azadine, Onureg, VIDAZA, Vidaza
Pipeline
Phase 2: 6Phase 3: 2Phase 1/2: 3
Top Sponsors
- Timothy Pardee1
- The First Affiliated Hospital of Soochow University1
- Technische Universität Dresden1
- Sumitomo Pharma America, Inc.1
- Ruijin Hospital1
Indications
- Cancer11
- Acute Myeloid Leukemia4
- Leukemia, Myeloid, Acute2
- Myelodysplastic Syndromes2
- Leukemia, Lymphocytic, Acute1
Other6 trials
Birmingham, Alabama1 trial
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
University of Alabama at Birmingham
Phase 3
Gilbert, Arizona1 trial
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Banner MD Anderson Cancer Center
Phase 3
Newport Beach, California1 trial
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Hoag Family Cancer Center
Phase 1/2
Boston, Massachusetts1 trial
Winston-Salem, North Carolina1 trial
Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
Atrium Health Wake Forest Baptist Medical Center
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.